Litcius/Paper detail

Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters

William L. Conte, Lilian Golzarri‐Arroyo

2022Multiple Sclerosis and Related Disorders31 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMultiple sclerosisOcrelizumabImmunologyNatalizumabAntibodyVaccinationPopulationImmune systemAntibody responseRituximabEnvironmental healthSARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders
Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters | Litcius